Holen Sie sich die Stockscreener-App
22.16
1.51%
-0.34
Handel nachbörslich:
22.16
Schlusskurs vom Vortag:
$22.50
Offen:
$22.94
24-Stunden-Volumen:
496.63K
Relative Volume:
1.12
Marktkapitalisierung:
$1.61B
Einnahmen:
$384.10M
Nettoeinkommen (Verlust:
$-9.07M
KGV:
-158.29
EPS:
-0.14
Netto-Cashflow:
$11.10M
1W Leistung:
+4.18%
1M Leistung:
+12.77%
6M Leistung:
-12.27%
1J Leistung:
+8.31%
1-Tages-Spanne:
$22.12
$22.94
1-Wochen-Bereich:
$20.39
$22.94
52-Wochen-Spanne:
$16.56
$28.15
Kiniksa Pharmaceuticals International Plc Stock (KNSA) Company Profile
Firmenname
Kiniksa Pharmaceuticals International Plc
Sektor
Telefon
(781) 431-9100
Adresse
23 OLD BOND STREET, FLOOR 3, LONDON
Vergleichen Sie KNSA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KNSA
Kiniksa Pharmaceuticals International Plc
|
22.16 | 1.61B | 384.10M | -9.07M | 11.10M | -0.14 |
|
ZTS
Zoetis Inc
|
160.06 | 71.67B | 9.26B | 2.49B | 2.30B | 5.47 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.03 | 47.44B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
10.19 | 46.08B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.46 | 18.86B | 16.54B | -1.64B | 749.00M | -1.45 |
|
ITCI
Intra Cellular Therapies Inc
|
131.36 | 13.97B | 612.78M | -86.37M | -62.91M | -0.87 |
Kiniksa Pharmaceuticals International Plc Stock (KNSA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-09-13 | Eingeleitet | Jefferies | Buy |
| 2024-05-03 | Eingeleitet | Wells Fargo | Overweight |
| 2020-06-29 | Bestätigt | BofA Securities | Buy |
| 2020-04-01 | Eingeleitet | BofA/Merrill | Buy |
| 2019-03-11 | Eingeleitet | Barclays | Overweight |
| 2018-12-12 | Bestätigt | Wedbush | Outperform |
| 2018-06-19 | Eingeleitet | JMP Securities | Mkt Outperform |
Alle ansehen
Kiniksa Pharmaceuticals International Plc Aktie (KNSA) Neueste Nachrichten
Taking on analysts’ expectations and winning: Kiniksa Pharmaceuticals International Plc (KNSA) - SETE News
Citigroup Initiates Coverage on Kiniksa Pharmaceuticals International With Buy Rating, $40 Price Target - Marketscreener.com
Kiniksa Pharmaceuticals COO sells shares worth $261,333 - Investing.com
Kiniksa Pharmaceuticals COO sells shares worth $261,333 By Investing.com - Investing.com UK
Deeper Dive: Understanding Kiniksa Pharmaceuticals International Plc (KNSA) Through its Various Ratios - The Dwinnex
Kiniksa Pharmaceuticals Stock Is Attractive From Valuation Perspective-JP Morgan Analyst - Benzinga
Is Kiniksa Pharmaceuticals International, plc (KNSA) the Best UK Growth Stock to Buy Now? - Insider Monkey
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Shares Sold by Rhumbline Advisers - Defense World
New York State Common Retirement Fund Has $302,000 Position in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) - Defense World
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Sees Large Increase in Short Interest - Defense World
Is Kiniksa Pharmaceuticals International, plc (KNSA) the Best Small Cap Pharma Stocks to Buy Now? - Insider Monkey
Is Kiniksa Pharmaceuticals International, plc (KNSA) the Best Small Cap Pharma Stock to Buy Now? - Insider Monkey
12 Best Small Cap Pharma Stocks to Buy Now - Insider Monkey
Decoding Kiniksa Pharmaceuticals International PLC (KNSA): A Str - GuruFocus.com
Kiniksa Pharmaceuticals Shifts Strategic Focus with Key Agreement Terminations and 2024 Financial Results - Defense World
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Q4 2024 Earnings Call Transcript - Insider Monkey
Kiniksa Pharmaceuticals Q4 2024 Earnings: Revenue at $122.5M, Mi - GuruFocus.com
Kiniksa issues updates on abiprubart, KPL-387, mavrilimumab - MSN
Big Pipeline Updates From Kiniksa Pharmaceuticals (NASDAQ:KNSA) - Seeking Alpha
Kiniksa to launch Phase 2/3 trial for heart drug KPL-387 - Investing.com India
Kiniksa Pharmaceuticals Swings to Q4 Loss, Revenue Increases -February 25, 2025 at 08:20 am EST - Marketscreener.com
Kiniksa to launch Phase 2/3 trial for heart drug KPL-387 By Investing.com - Investing.com South Africa
Earnings Flash (KNSA) Kiniksa Pharmaceuticals Posts Q4 Total Revenue $122.5M, vs. FactSet Est of $123.4M - Marketscreener.com
Earnings Flash (KNSA) Kiniksa Pharmaceuticals Posts Q4 Net Loss $-0.12 a Share, vs. FactSet Est of $-0.06 Loss - Marketscreener.com
Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Portfolio Execution - The Manila Times
Kiniksa Pharmaceuticals Reports Strong Q4 2024 Financials with ARCALYST Revenue of $417 Million and Anticipates 2025 Sales Growth - Nasdaq
Kiniksa Pharmaceuticals Announces Development of KPL-387 in - GlobeNewswire
Can Kiniksa's 79% Revenue Surge Continue as Company Shifts Pipeline Focus? - StockTitan
Can Kiniksa's New Pericarditis Drug Build on Its $800M ARCALYST Success? - StockTitan
KNSAKiniksa Pharmaceuticals International, plc Latest Stock News & Market Updates - StockTitan
Kiniksa Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025 - GlobeNewswire
Kiniksa Pharmaceuticals COO Tessari Eben sells $273,980 in shares - MSN
Kiniksa Pharmaceuticals COO sells shares worth $273,980 - MSN
Kiniksa Pharmaceuticals: Strong Improvement In Arcalyst Revenue, But Risks Remain - Seeking Alpha
Kiniksa Pharmaceuticals COO sells shares worth $273,980 By Investing.com - Investing.com Canada
Kiniksa Pharmaceuticals International Plc (KNSA) Stock: Tracking the Weekly Performance - The News Heater
Is Kiniksa Pharmaceuticals International Plc (KNSA) a opportunity to investors? - US Post News
Keeping an Eye on Kiniksa Pharmaceuticals International Plc (KNSA) After Insider Trading Activity - Knox Daily
Stock Market Recap: Kiniksa Pharmaceuticals International Plc (KNSA) Concludes at 18.88, a -3.67 Surge/Decline - The Dwinnex
Exploring High Growth Tech Stocks in the United States - Simply Wall St
Kiniksa Pharmaceuticals Reports Strong 2024 Financial Results and Provides 2025 Revenue Guidance - Defense World
Kiniksa Pharmaceuticals COO Tessari Eben sells shares worth $255,413 - Investing.com India
Evolving Landscape of Cardiology Segment: Key Market Insights of Latest Published Rare Cardiovascular Diseases Report — Giant-Cell Arteritis, Pulmonary Arterial Hypertension, and Restrictive Cardiomyopathy | DelveInsight - GlobeNewswire Inc.
Kiniksa Pharmaceuticals Reports Preliminary 2024 Net Product Revenue and Provides 2025 Net Product Revenue Guidance - The Manila Times
Kiniksa Pharmaceuticals Reports Preliminary 2024 Net - GlobeNewswire
Kiniksa's ARCALYST Soars 79% to $416M in 2024, Projects Strong 2025 Growth to $580M - StockTitan
Kiniksa Pharmaceuticals to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan
Kiniksa Pharmaceuticals to Present at 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewswire
Kiniksa Pharmaceuticals COO Tessari Eben sells shares worth $470k - Investing.com
Finanzdaten der Kiniksa Pharmaceuticals International Plc-Aktie (KNSA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.77%
0.63%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):